論文

査読有り 最終著者
2017年6月

Identification and characterization of a thermally cleaved fragment of monoclonal antibody-A detected by sodium dodecyl sulfate-capillary gel electrophoresis

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
  • Kei Kubota
  • ,
  • Naoki Kobayashi
  • ,
  • Masayuki Yabuta
  • ,
  • Motomu Ohara
  • ,
  • Toyohiro Naito
  • ,
  • Takuya Kubo
  • ,
  • Koji Otsuka

140
開始ページ
98
終了ページ
104
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jpba.2017.03.027
出版者・発行元
ELSEVIER SCIENCE BV

This report describes a novel, comprehensive approach to identifying a fragment peak of monoclonal antibody-A (mAb-A), detected by sodium dodecyl sulfate-capillary gel electrophoresis (SDS-cGE). The fragment migrated close to the internal standard (10 kDa marker) of SDS-cGE and increased about 0.5% under a 25 degrees C condition for 6 months. Generally, identification of fragments observed in SDS-cGE is challenging to carry out due to the difficulty of collecting analytical amounts of fractionations from the capillary. In this study, in-gel digestion peptide mapping and reversed phase liquid chromatography mass spectrometry (RPLC MS) were employed to elucidate the structure of the fragment. In addition, a Gelfree 8100 fractionation system was newly introduced to collect the fragment and the fraction was applied to the structural analysis of a mAb for the first time. These three analytical methods showed comparable results, proving that the fragment was a fraction of heavy chain HC1-104. The fragment contained complementarity determining regions (CDRs), which are significant to antigen binding, and thus would affect the efficacy of mAb-A. In addition, SDS-cGE without the 10 kDa marker was demonstrated to clarify the increased amount of the fragment, and the experiment revealed that the fragment increases 0.2% per year in storage at 5 degrees C. The combination of the three analytical methodologies successfully identified the impurity peak detected by SDS-cGE, providing information critical to assuring the quality and stability of the biotherapeutics. (C) 2017 Elsevier B.V. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.jpba.2017.03.027
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000402850500011&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.jpba.2017.03.027
  • ISSN : 0731-7085
  • eISSN : 1873-264X
  • Web of Science ID : WOS:000402850500011

エクスポート
BibTeX RIS